The Lawyer Asia Pacific 150 is the only research report to provide a ranking of the top 100 independent local firms and top 50 global firms in the region. The report offers critical review of some of the fastest growing firms and their strategies, a country-by-country guide to leading legal advisers and legal services market trends, plus exclusive insight into the current business development opportunities in the Asia Pacific. Read more
This year, The Lawyer’s annual ranking of the largest UK law firms by turnover is available as an interactive, digital benchmarking tool. For the first time this will allow you to manipulate each data set against the metrics of your choice.
Lovells has strengthened its life sciences group with the addition of former Merck Sharp & Dohme legal director Marc Dalby.
At Merck Sharp & Dohme, which is a client of the firm and the UK subsidiary of Merck & Co, Dalby was company secretary in addition to legal director. He has not yet been replaced.
Dalby joined the City firm last Tuesday (8 May) as a consultant in the life sciences team, as first revealed on www.thelawyer. com (8 May). He focuses on the regulation of pharmaceutical promotion, competition law, product liability and data exclusivity.
Dalby is a longstanding member of the legal affairs committee of the Association of the British Pharmaceutical Industry (ABPI) and has sat on a number of ABPI working groups and subcommittees.
He was called to the bar in 1986 and went on to practise at 5 King's Bench Walk. He has also held legal positions at Lloyd's of London and Napp Pharmaceuticals.